AHCA/NCAL: COVID-19 Update | CDC and FDA Authorize Additional Dose of COVID-19 Vaccine for Immunocompromised Individuals
CDC and FDA Authorize Additional Dose of COVID-19 Vaccine for Immunocompromised Individuals
The FDA has amended the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals. The CDC’s Advisory Committee on Immunization Practices followed the authorization with a recommendation that an additional dose of an mRNA COVID-19 vaccine (i.e., Pfizer or Moderna), after an initial two-dose primary mRNA COVID-19 vaccine series, be considered for people with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments.
Other COVID-19 Updates
NHSN Seeking COVID-19 Vaccine Supply Information: All National Healthcare Safety Network facility users should have received an email from NHSN detailing the importance of accurate and timely information on COVID-19 Vaccine supply. Read More
COVID-19 Webinars
Best Practices for Vaccine Mandates
Thursday, August 19 at 3:00 PM ET
Hosted by AHCA/NCAL
Register
Please email COVID19@ahca.org for additional questions, or visit ahcancal.org/coronavirus for more information.
NYSHFA/NYSCAL CONTACTS:
Jackie Pappalardi, RN, BSN
Executive Director
518-462-4800 x16
Lisa Volk, RN, B.P.S., LNHA
Director, Clinical & Quality Services
518-462-4800 x15
